Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Everolimus CAS 159351-69-6 Certican

Everolimus CAS 159351-69-6 Certican 

Payment Terms: T/T,L/C,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C53H83NO14
Production Capacity: 10KG/Year
Delivery Date: within 7 days
Formula: C53H83NO14
Mol. mass: 958.224 g/mol
Flash(ing) point: 557.8°C
Means of Transport: Ocean,Land,Air
Packing: According to customer requi...
Boiling point: 998.7°C at 760 mmHg
Density: 1.18g/cm3
Vapour pressure: 0mmHg at 25°C

Everolimus is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin

Everolimus(CAS: 159351-69-6)



Molecular Formula


Molecular Weight






Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).

It is currently used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors for use in a number of cancers.

It is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitorin oncology. Everolimus also available with Biocon with the brand name of Evertor.

 Approvals and indications

Everolimus is approved for various conditions:

  • Advanced kidney cancer (approved in March 2009)

  • Prevention of organ rejection after renal transplant(April 2010)

  • Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (October 2010)

  • Progressive or metastatic pancreatic neuroendocrine tumors not surgically removable (May 2011)

  • Breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer, in conjunction with exemestane (July 2012)

  • Prevention of organ rejection after liver transplant(Feb 2013)

Clinical trials

As of October 2010, Phase III trials are under way in gastric cancer, hepatocellular carcinoma and lymphoma. The use of everolimus in refractorychronic graft-versus-host disease has been reported in 2012.

Interim phase III trial results in 2011 showed that adding Afinitor (everolimus) to exemestane therapy against advanced breast cancer can significantly improve progression-free survival compared with exemestane therapy alone. However, everolimus increases mortality in cancer patients.

Furthermore, there is a study that shows that there is a different sensitivity to Everolimus between patients depending on their genome. Through a Phase II Clinical Trial done in patients that presented advanced metastasic bladder carcinoma (NCT00805129)  they found just one person that positively responded to Everolimus treatment for 26 months. Thus, they decided to sequence the genome of this patient and to compare it to different reference genomes and to other patients' genomes. This way, they discovered that mutations in TSC1 lead to an increase in recurrence and to an increase in the response time to Everolimus. Thus, it has been determined that Everolimus is more efficient in those patients that present somatic mutations in TSC1.


In a similar fashion to other mTOR inhibitors its effect is solely on the mTORC1 protein complex and not on the mTORC2 complex. This can lead to a hyper-activation of the kinase AKT via inhibition on the mTORC1 negative feedback loop while not inhibiting the mTORC2 positive feedback to AKT. This AKT elevation can lead to longer survival in some cell types. Hence, Everolimus plays an important role in cell growth, cell proliferation and cell survival. mTORC1 action is modulated by several mitogens, growth factors and nutrients.

TSC1 and TSC2 (which are the genes involved in tuberous sclerosis disease) act as tumor suppressor genes by regulating mTORC1 activity. Thus, either the loss or inactivation of one of these genes lead to the activation of mTORC1.

Everolimus binds to its protein receptor FKBP12, which directly interacts with mTORC1 inhibiting its downstream signaling. As a consequence, mRNAs that codify proteins implicated in the cell cycle and in the glycolisis process are impared or altered, so tumor growth is inhibited. Hence, Everolimus inhibits tumor cells' growth and proliferation.

Use in vascular stents

Everolimus is used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Abbott Vascular produces an everolimus-eluting stent called the Xience V. It utilizes the Multi-Link Vision cobalt chromium stent platform and Novartis' everolimus. The product is also currently in use in the United States and as an investigational device in Japan. A similar version called the PROMUS Everolimus-Eluting Coronary Stent System is produced by Boston Scientific and it is currently available in the United States and most major European and Asia-Pacific markets.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: